Phathom Pharmaceuticals (NASDAQ: PHAT) stock is soaring 10.50% in pre-market trading on Thursday following the release of its impressive third-quarter 2025 financial results. The pharmaceutical company significantly outperformed analyst expectations, demonstrating strong growth and improved financial health.

The company reported Q3 revenue of $49.5 million, beating the consensus estimate of $46.5 million and marking a substantial 25% increase quarter-over-quarter. This growth was primarily driven by a 28% rise in filled VOQUEZNA prescriptions, supported by strategic sales force retargeting efforts. Phathom's adjusted earnings per share (EPS) also exceeded expectations, coming in at -$0.15 compared to the estimated -$0.56, representing a 72.48% beat.

In light of these strong results, Phathom Pharmaceuticals has updated its full-year 2025 revenue guidance to $170-$175 million, up from the previous range of $165-$175 million. The company also reported significant cost savings, with cash operating expenses down 43% quarter-over-quarter, aligning with its cost-saving plans. These factors, combined with stable commercial coverage for over 80% of U.S. lives, have contributed to the positive market reaction and heightened investor confidence in Phathom's growth trajectory. The company's focus on gastrointestinal specialists and the potential for VOQUEZNA exclusivity through May 2032 further bolster its long-term prospects.